CRISABOROLE | N207695 | ANACOR PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Anacor Pharmaceuticals, LLC, et al., v. Macleods Pharmaceuticals Ltd., et al., 4 patentsANDA 216301crisaborole | D. Del. | 2021-09-24 | Terminated 2023-08-24 | — |
Anacor Pharmaceuticals, Inc. et al v. Teva Pharmaceuticals Development, Inc. et al 3 patentsANDA 215914crisaborole | D. Del. | 2021-09-24 | Terminated 2023-06-15 | — |
| D. Del. | 2021-09-24 | Terminated 2023-07-19 | — | |
| D. Del. | 2021-09-24 | Terminated 2023-08-24 | — | |
| D. Del. | 2021-09-24 | Terminated 2023-05-08 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Hyman, Phelps & McNamara, PC FDA-2017-P-4409 · 5 docket documents The law firm Hyman, Phelps & McNamara, P.C. filed this citizen petition requesting that the FDA require Synergy Pharmaceuticals to revise the approved package insert for Trulance (plecanatide), an NDA 208745 product approved January 19, 2017 for chronic idiopathic constipation in adults. The petitio | Other | 2017-07-25 | Partially Denied | Hyman, Phelps & McNamara, PC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$12.65
per gm
Lowest NADAC/Unit
$10.69
per gm
Brand NDCs
2
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 55724021121EUCRISA 2% OINTMENT | $12.65 | GM | Brand | — | 2026-06-17 |
| 55724021111EUCRISA 2% OINTMENT | $10.69 | GM | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Code | Date | Status |
|---|---|---|
| D-191 | Apr 3, 2026 | Expired |